Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
REVB · NASDAQ · Pharmaceutical Preparations
Revelation Biosciences (REVB) · oqro.io/stocks/REVB · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Revelation Biosciences was filed in the last 90 days. The latest on record was on Apr 18, 2023.
Since 2020, Revelation Biosciences insiders reported 8 open-market purchases and 13 sales on Forms 4 and 5, with purchases in 2 different years, most recently 2023.
No open-market sale by an insider of Revelation Biosciences (REVB) was filed with the SEC in the last 90 days.
No trade in Revelation Biosciences (REVB) was disclosed by a member of Congress in the last 12 months.
Revelation Biosciences's next results are expected on Feb 24, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$3.50−0.19 (−5.15%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
−85.3% (−$20.30) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $23.80 on Nov 20, 2025 to $3.50 on Nov 20, 2026 (−85.3%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in San Diego, Ca.
Last 12 months
−84.6%
Market value
$2.52M
S&P 500 +8.0% over the same dates. Prices adjusted for splits and dividends.
Short interest: 13K shares sold short (1.9% of shares outstanding), +93.7% vs the previous count, 1.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Nothing reported yet
New filings show up here as soon as they are processed.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insiders of Revelation Biosciences reported 8 open-market purchases and 13 sales since 2020; purchases in 2 different years, most recently 2023.
| Year | Bought | Sold |
|---|---|---|
| 2023 | $60K2×2 trades | $43K7×7 trades |
| 2022 | $244K6×6 trades | — |
| 2021 | — | $6.6M3×3 trades |
| 2020 | — | $143K3×3 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
No Schedule 13D or 13G filing on REVB over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Top officer leaving
“The Amended Employment Agreements reflect the following material changes: • An increase in the change in control severance benefits to be received by each of the CEO and CFO in the event he experiences a “covered termination” (as defined in the Amended Employment Agreement) during the period beginning three months prior to a “change in control” (as defined in the Amended Employment Agreement) and”
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Revenue
—
Free cash flow, last 12 months
−$2.36M
This quarter −$2.36M
Net debt
—
Debt —, cash $9.12M, at Sep 30, 2026
Net income, last 12 months
−$12.2M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 5, 2026.
Revenue and earnings history, 7 fiscal yearsEarnings dates and the stock's moves
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 4,000 words.
Revelation is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. We are developing a pipeline of potential high-value products based on Gemini. Gemini is our proprietary formulation of PHAD an established TLR4 agonist that can stimulate the human body’s innate immune response to prevent and treat disease. Our current Gemini based programs consist of: GEM-AKI, which is being developed as a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, which is being developed as a potential therapy for the prevention and treatment of chronic kidney disease.
And 10 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Feb 26, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Latest annual report filed Feb 26, 2026, compared with the one filed Mar 6, 2025. Read the filing
None reported.
Source: SEC EDGAR, Form 10-K filed Feb 26, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Last results
Nov 5, 2026
Within the 30 days after it, until Dec 5, 2026
Next results, expected
Feb 24, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
Not enough history
From Revelation Biosciences's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Revelation Biosciences's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Off-exchange trading: about 238 thousand shares a week traded away from the exchanges over the latest 4 published weeks, 9,336 of them on ATS. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: INTELLIGENT CROSS LLC (15.5%), POSIT (10.4%), SIGMA X2 (10.0%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others.